Applied Materials Vs. KLA Corporation: This AI Infrastructure Play Is A Better Buy

Applied Materials reported Q2 FY2026 revenue of $7.91B (beat consensus) and raised its calendar-2026 semiconductor equipment growth outlook to >30% from ~20%, citing record performance; Semiconductor Systems revenue hit $5.965B with operating margin improving to 35.1% from 32.8%. KLA posted Q3 FY2026 revenue of $3.415B (beat consensus), with process control revenue of $3.083B (~90% of sales) and a non-GAAP gross margin guide of 61.75% for June, while free cash flow fell to $622M (-36.97% YoY). Despite softer cash conversion (AMAT FCF down 80.21% YoY to $210M), both firms’ AI-driven capex tailwinds and AMAT’s sharper growth call should support upside, with key watchpoints being cash conversion and KLA’s $3.575B June-quarter target.

Analysis

This is a better read-through for the supply chain than for the headline names alone. AMAT’s breadth means it is the cleaner proxy for incremental AI capex: leading-edge logic, HBM-related tool intensity, and advanced packaging all pull through the same order book, which should also support TSM, SKHYV, and packaging-adjacent names like ASMVY if the buildout stays on schedule. The flip side is that breadth dilutes moat quality and makes AMAT more sensitive to any pause in fab-starts or customer digestion.

KLAC is the higher-quality, lower-variance compounder, but it is also the more “perfect execution” stock in a late-cycle spend environment. If wafer-start growth cools while AI capex rotates from installation to qualification, KLAC can still print strong margins and buybacks, yet the multiple may not expand as much as AMAT’s because the market pays up less for a narrower end-market. That makes KLAC the safer business and potentially the worse short, but not necessarily the better near-term long.

The key risk is cash conversion, not reported revenue. AMAT’s weak FCF profile usually normalizes only if working capital unwinds; if it doesn’t, that is often an early warning that shipments are outrunning end-demand. Over 1-3 months, the stock can trade on guidance revision momentum; over 6-18 months, the real falsifier is any sign that China restrictions or HBM packaging bottlenecks are delaying tool deployment rather than merely shifting it between customers.

Contrarian view: the market may be underestimating how much of the AI equipment cycle is now a packaging and process-control cycle, not just a wafer-fab cycle. That argues for owning the entire ecosystem, but selectively: the best risk/reward is not chasing the highest-quality name after a beat, it is owning the one with the biggest revenue leverage while hedging the valuation risk. The thesis breaks if AMAT’s next quarter still shows poor cash conversion or if KLAC’s process-control share gains reaccelerate enough to re-rate the quality premium.

Key Decisions for Investors

• Buy AMAT on any 2-3% post-earnings pullback; target 8-12% upside over 4-8 weeks as the market prices the raised equipment-growth outlook, but reduce/exit if next-quarter FCF stays below ~$500M or guide is cut.
• Pair trade: long AMAT / short KLAC, equal dollar-weighted, for 1-2 months. Thesis is that breadth-and-beta should outperform quality-and-defensiveness while AI capex remains in install mode; stop if KLAC materially outperforms on next commentary or AMAT cash conversion worsens again.
• Add TSM and SKHYV as second-order beneficiaries on any semiconductor capex dip; the trade is for 6-12 months and works only if tool orders are converting into actual node migrations and HBM capacity additions.
• Use ASMVY as a watchlist beneficiary, not a conviction long, until there is proof that advanced packaging spend is translating into backlog and not just customer timing noise.